Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 2251 AL 2265

DYT16: the original cases

Camargos S, Lees AJ, Singleton A, Cardoso F.

J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):1012-4. doi: 10.1136/jnnp-2012-302841. Epub 2012 Jul 28.

Long-term benefit of bilateral subthalamic deep brain stimulation on camptocormia in Parkinson's disease

Lyons M, Boucher O, Patel N, Birch B, Evidente V.

Turk Neurosurg. 2012;22(4):489-92. doi: 10.5137/1019-5149.JTN.3857-10.0.

Human Mendelian pain disorders: a key to discovery and validation of novel analgesics

Goldberg YP, Pimstone SN, Namdari R, Price N, Cohen C, Sherrington RP, Hayden MR.

Clin Genet. 2012 Oct;82(4):367-73. doi: 10.1111/j.1399-0004.2012.01942.x. Epub 2012 Aug 13.

A diet low in animal fat and rich in N-hexacosanol and fisetin is effective in reducing symptoms of Parkinson's disease

Renoudet VV, Costa-Mallen P, Hopkins E.

J Med Food. 2012 Aug;15(8):758-61. doi: 10.1089/jmf.2012.0060. Epub 2012 Jun 25.

Parkinson's disease, L-DOPA, and endogenous morphine: a revisit

Stefano GB, Mantione KJ, Králíčková M, Ptacek R, Kuzelova H, Esch T, Kream RM.

Med Sci Monit. 2012 Aug;18(8):RA133-137. doi: 10.12659/msm.883259.

Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research

Yagi T, Kosakai A, Ito D, Okada Y, Akamatsu W, Nihei Y, Nabetani A, Ishikawa F, Arai Y, Hirose N, Okano H, Suzuki N.

PLoS One. 2012;7(7):e41572. doi: 10.1371/journal.pone.0041572. Epub 2012 Jul 25.

Validation and the future of stimulation therapy of the primary motor cortex

Saitoh Y.

Neurol Med Chir (Tokyo). 2012;52(7):451-6. doi: 10.2176/nmc.52.451.

Spinal cord stimulation for the treatment of abnormal posture and gait disorder in patients with Parkinson's disease

Agari T, Date I.

Neurol Med Chir (Tokyo). 2012;52(7):470-4. doi: 10.2176/nmc.52.470.

Caffeine for treatment of Parkinson disease: a randomized controlled trial

Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Rios Romenets S, Altman R, Chuang R, Shah B.

Neurology. 2012 Aug 14;79(7):651-8. doi: 10.1212/WNL.0b013e318263570d. Epub 2012 Aug 1.

Caffeine in Parkinson disease: better for cruise control than snooze patrol?

Schwarzschild MA.

Neurology. 2012 Aug 14;79(7):616-8. doi: 10.1212/WNL.0b013e318263580e. Epub 2012 Aug 1.

Susceptibility of mitochondrial electron-transport complexes to oxidative damage. Focus on cytochrome c oxidase

Musatov A, Robinson NC.

Free Radic Res. 2012 Nov;46(11):1313-26. doi: 10.3109/10715762.2012.717273. Epub 2012 Sep 5.

Accuracy of Timed Up and Go Test for screening risk of falls among community-dwelling elderly

Alexandre TS, Meira DM, Rico NC, Mizuta SK.

Rev Bras Fisioter. 2012 Sep-Oct;16(5):381-8. doi: 10.1590/s1413-35552012005000041. Epub 2012 Aug 2.

Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models

Kramer T, Lo Monte F, Göring S, Okala Amombo GM, Schmidt B.

ACS Chem Neurosci. 2012 Mar 21;3(3):151-60. doi: 10.1021/cn200117j. Epub 2012 Jan 18.

Rafts, Nanoparticles and Neural Disease

Gulati V, Wallace R.

Nanomaterials (Basel). 2012 Aug 6;2(3):217-250. doi: 10.3390/nano2030217.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias